News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc. Heart-Failure Drug, Inspra Helps Milder Patients
November 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO (Reuters) - People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Postmarket research
MORE ON THIS TOPIC
Neuroscience
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
December 23, 2025
·
2 min read
·
Nick Paul Taylor
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
December 23, 2025
·
1 min read
·
Annalee Armstrong
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
